For a generation, the pull toward minimally invasive medicine has felt almost inevitable — less cutting, faster recovery, fewer fears. Yet a landmark 2022 trial involving nearly 1,900 patients across five countries quietly redraws that assumption for those facing the gravest form of leg artery disease, where amputation is not a distant risk but an approaching reality. When a patient's own vein is available for grafting, traditional bypass surgery reduces the need for repeat procedures by nearly two-thirds and lowers amputation risk by more than a quarter — without adding danger to the heart or
Bypass Surgery Outperforms Minimally Invasive Procedures for Severe Leg Artery Disease
Without treatment, 20-40% of chronic limb-threatening ischemia patients face major leg amputation; bypass surgery reduced amputation risk by 27% compared to endovascular procedures.
Bypass surgery led to better outcomes for limb preservation
Mark
Why did surgeons move away from bypass surgery in the first place if it works better?
Mimi
Because endovascular procedures arrived and looked like progress—less invasive, faster recovery, fewer complications in the short term. But nobody had actually studied which one prevented amputations better in the sickest patients. The trend happened before the evidence.
Mark
So this trial is saying open surgery is always better?
Mimi
Only when you have a good leg vein to use. If that vein isn't suitable, endovascular and bypass perform about the same. The advantage of surgery seems tied to the quality of the graft material available.
Mark
What does a 27 percent reduction in amputations actually mean for a patient?
Mimi
It means if you're facing CLTI, your odds of keeping your leg improve significantly. Without treatment, one in three or four patients lose a limb. With bypass surgery using a good vein, fewer of those amputations happen.
Mark
Did patients die more often from one approach than the other?
Mimi
No. That's what surprised people. The assumption was that open surgery—cutting someone open, harvesting a vein—would be riskier. But death rates were identical between the groups. The surgery wasn't more dangerous; it was more effective.
Mark
How long did researchers follow these patients?
Mimi
Up to seven years for the group with good veins. That's long enough to see whether the benefits held or whether the endovascular stents failed and required repeated procedures. The bypass grafts stayed open longer.
Mark
What happens now with this information?
Mimi
Clinical guidelines will likely shift. Surgeons will probably recommend bypass surgery more often for CLTI patients who have suitable veins. It changes the conversation from "let's try the less invasive approach first" to "if you have a good vein, surgery gives you the best shot at keeping your leg."
El Pulso
- Millions live with peripheral artery disease, and for those who reach its most severe stage, the countdown to potential limb loss is already running — 20 to 40 percent face major amputation without intervention.
- The quiet migration toward catheter-based, minimally invasive procedures over the past two decades was driven by intuition and convenience, not by hard clinical evidence for the sickest patients.
- The BEST-CLI trial — 1,830 patients, 150 centers, five countries, up to seven years of follow-up — was built precisely to fill that evidentiary void and force a reckoning with assumptions.
- For patients with a usable leg vein, bypass surgery delivered a 33 percent reduction in major limb events, 65 percent fewer repeat procedures, and 27 percent fewer amputations, with no added risk of death, heart attack, or stroke.
- The advantage vanished when no suitable leg vein existed, revealing that the surgical benefit is real but conditional — dependent on anatomy, not ideology.
- Clinical practice guidelines for vascular disease now face pressure to realign with the data, steering appropriate patients back toward the operating room rather than the catheterization suite.
For a generation, the pull toward minimally invasive medicine has felt almost inevitable — less cutting, faster recovery, fewer fears. Yet a landmark 2022 trial involving nearly 1,900 patients across five countries quietly redraws that assumption for those facing the gravest form of leg artery disease, where amputation is not a distant risk but an approaching reality. When a patient's own vein is available for grafting, traditional bypass surgery reduces the need for repeat procedures by nearly two-thirds and lowers amputation risk by more than a quarter — without adding danger to the heart or brain. The evidence, long absent, has now arrived: for this particular crossroads, the older path may be the wiser one.
For two decades, vascular medicine drifted steadily toward the catheter and away from the scalpel. The logic was intuitive: if a balloon and a stent could reopen a blocked artery, why subject a patient to open surgery? But intuition is not evidence, and for patients facing chronic limb-threatening ischemia — the stage of peripheral artery disease where tissue dies, wounds refuse to heal, and amputation becomes probable — that distinction matters enormously.
The BEST-CLI trial, launched in 2014 and presented at the American Heart Association's 2022 Scientific Sessions, was designed to settle the question. Researchers enrolled 1,830 patients across 150 centers in the United States, Canada, Italy, Finland, and New Zealand. The typical participant was 67 years old, often diabetic, frequently a former smoker, and staring down the real possibility of losing a limb. Patients were divided into two groups based on a single anatomical variable: whether they had a suitable leg vein available for bypass grafting.
In the larger group — 1,434 patients with usable saphenous veins — those who received traditional bypass surgery fared dramatically better. They experienced 33 percent fewer major adverse limb events overall, 65 percent fewer repeat procedures, and 27 percent fewer amputations than those treated with endovascular techniques. Crucially, rates of death, heart attack, and stroke were identical between the two approaches, dismantling the assumption that open surgery carries inherently greater systemic risk.
The second group told a more complicated story. When no suitable leg vein was available and surgeons had to rely on arm veins or synthetic grafts, bypass surgery offered no measurable advantage over the minimally invasive alternative. The benefit, it turns out, is real but conditional.
Principal investigator Alik Farber of Boston Medical Center described the findings as a direct challenge to the prevailing habit of defaulting to endovascular treatment first out of caution. The trial was not without limitations — site-level variation in technique, lower-than-expected female enrollment, and potential selection bias among them. But with follow-up stretching to seven years and outcomes measured in preserved limbs and sustained lives, the BEST-CLI trial stands as the most rigorous comparison yet conducted. For patients with a good vein and an acceptable surgical risk, the data now speak plainly: bypass surgery offers the stronger path forward.
For decades, the trend in vascular surgery has been unmistakable: as minimally invasive techniques became easier to perform and more widely available, surgeons and patients alike gravitated toward them. Why undergo open surgery when a catheter and a stent could do the job? But a major clinical trial presented in November 2022 at the American Heart Association's Scientific Sessions challenges that assumption, at least for patients facing the most dire vascular crisis: chronic limb-threatening ischemia, the stage of peripheral artery disease where amputation becomes a real possibility.
Peripheral artery disease occurs when fatty plaque narrows the arteries carrying blood to the legs and feet. More than 200 million people worldwide have it, and the numbers are climbing as populations age and Type 2 diabetes spreads. When the disease advances to its severe form—chronic limb-threatening ischemia, or CLTI—patients experience rest pain, wounds that won't heal, tissue death, and a grim arithmetic: without treatment, between 20 and 40 percent will lose a leg to amputation. The stakes could not be higher.
Two main approaches exist to restore blood flow. Bypass surgery creates a detour around the blockage using either a vein harvested from the patient's own leg or an artificial vessel. Endovascular procedures, by contrast, thread a balloon-tipped catheter into the blocked artery, inflate it to widen the passage, and leave behind a stent to hold it open. Both are considered standard care, yet until recently, little hard evidence existed about which worked better for CLTI patients. The BEST-CLI trial—Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia—was designed to answer that question.
Beginning in 2014, researchers enrolled 1,830 patients across 150 centers in the United States, Canada, Italy, Finland, and New Zealand. The typical participant was 67 years old, often diabetic, frequently a smoker, and facing the prospect of losing a limb. The trial divided patients into two groups based on whether they had a suitable leg vein available for bypass grafting. In the first group—1,434 patients with usable saphenous veins—half received bypass surgery and half received endovascular treatment. In the second group—396 patients without suitable leg veins—some had bypass surgery using an arm vein or synthetic graft, while others underwent endovascular procedures. Researchers then tracked major adverse limb events: repeat procedures and amputations above the ankle.
The results for Group 1 were striking. Patients who received bypass surgery using their own leg vein experienced a 33 percent reduction in major adverse limb events compared to those treated with endovascular procedures. More specifically, they had 65 percent fewer repeat interventions and 27 percent fewer amputations. Critically, there was no difference in death, heart attack, or stroke rates between the two groups—meaning the surgical approach was not more dangerous, despite the common assumption that open surgery carries greater risk. Group 2 told a different story: when suitable leg veins were unavailable, bypass surgery using an arm vein or artificial vessel offered no advantage over endovascular treatment.
Alik Farber, the principal investigator and chief of vascular surgery at Boston Medical Center, emphasized the significance of these findings. The trial, he noted, "debunks the idea that CLTI patients who need revascularization should have an endovascular procedure first due to concern that bypass surgery may be potentially more dangerous." For patients at acceptable surgical risk with a good vein available, the data now clearly favored the open surgical approach. The shift toward minimally invasive techniques over the past two decades, while understandable given their lower upfront burden, had not been grounded in solid evidence for this particular patient population.
The study did carry limitations. Selection bias may have influenced results, since individual centers decided which patients were suitable candidates. Surgical and endovascular techniques varied across sites. And the trial enrolled fewer women than expected. Still, the BEST-CLI trial represents the most comprehensive comparison to date, following patients for up to seven years and measuring outcomes that matter most: keeping limbs intact and patients alive. For vascular surgeons and their patients facing chronic limb-threatening ischemia, the message is now clearer: when a good vein is available, bypass surgery offers the best chance of avoiding amputation.
Citas Notables
This information debunks the idea that CLTI patients should have an endovascular procedure first due to concern that bypass surgery may be potentially more dangerous.— Alik Farber, principal investigator, Boston Medical Center
Quieres la nota completa?
Lee el original en News-Medical.net ↗
Health & Medicine